Firefly Neuroscience (AIFF) said Tuesday its BNA technology platform is able to assess a patient's biological brain age using cognitive data, potentially leading to a "scalable" approach to early screening for Alzheimer's patients.
The US Food and Drug Administration-approved platform used resting electroencephalography, or EEG, and cognitive EEG to assess the biological age of a person's brain, the company said.
Chief Technology Officer Gil Issachar said the technology "is capable of finding a significant disparity between brain age and chronological age, which could serve as a valuable risk factor for dementia."
Shares of the company soared more than 111% in Tuesday's premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。